Successful Desensitization to Daratumumab After a Severe Life-threatening Reaction in a Patient With Refractory Multiple Myeloma

Abstract

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as

Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization

“…Multiple protocols have been reported as single cases with few number of desensitizations for several ChD and mAb such as brentuximabvedotin [122,123], nivolumab [124], alemtuzumab [125,126], atezolizumab [127], bevacizumab [127,128], denosumab [129], daratumumab [130]and canakimumab [131]. Although this is not the scope of this article, considering the potential utility for the reader and the off-label use of some mAbs, a recent review of desensitization procedures performed with mAbs used in rheumatology has been reported [132].…”

Addressing hypersensitivity reactions induced by Daratumumab: A review of management approaches and preventive measures

“…They could happen either during the initial infusion or repeated infusions, therefore fast identification, efficient care, and suitable preventive measures are all that are required. 5 A variety of immune-mediated adverse effects, ranging in severity from moderate to life-threatening, are included in hypersensitivity reactions. These events may show up as cytokine release syndrome, delayed hypersensitivity reactions, or acute infusionrelated symptoms.…”